Natural compound Alternol as a novel therapeutic for prostate cancer treatment.
Year: 2020
Type: article
Abstract: cell culture experiments Alternol inhibits prostate cancer cell proliferation by causing cell cycle arrest, reduces the expression of Bcl-2 and other pro-survival proteins, increases the level of radical oxygen species by activating xanthine dehydrogenase, blunts mitochondrial aerobic respiration and ATP production, and triggers autophagy flux. However, there is no significant adverse effect on benign prostatic cells. Animal experiments demonstrated that Alternol significantly inhibits the growth of prostate cancer xenografts without obvious adverse effect on normal tissues and organs. Therefore, Alternol is expected to be developed as a new anti-prostate cancer therapy.
Source: PubMed Central
Authors: Haixia Xu, Zeqiang Zhou, Benyi Li
Institutions: Shenzhen University, University of Kansas Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3045134636